Tatsuo Kurokawa,
PhD
Chair, Fellows of DIA
President, Japan Self-Medication Industry
Dr. Tatsuo Kurokawa started his career as a government official of the Ministry of Health and Welfare (later the Ministry of Health, Labour and Welfare – MHLW) in Japan. After seven years of experience in good manufacturing processes and drug safety/monitoring, he was dispatched as an associate expert to the World Health Organization, Geneva and Manila Office. Upon his return to Japan, he worked in science and technology policy, and for the promotion of bilateral and multilateral international collaborations, including trade issues among industrialized countries. In 1989, Dr. Kurokawa was transferred to the New Drug Division where he was involved in anti-cancer drug evaluation; participated in launching the work of the International Council on Harmonisation (ICH) with colleagues from the European Commission and the US; and served as a member of the ICH Steering Committee up to ICH-3 (1995). In 1994, he became Director, Office of Appropriate Use of Drug; he then became Director of the Food Chemical Division, and was appointed as Director, Safety Division, MHLW. In 2004, Dr. Kurokawa was appointed as Councilor, Minister’s Secretariat on Pharmaceutical Affairs, MHLW, from which he retired in 2008 to serve as Professor, International Drug Development and Regulation, Faculty of Pharmaceutical and Medical Sciences at Keio University. In 2016, he retired from Keio University and became President of the Japan Self-Medication Industry.
Dr. Kurokawa is a pharmacist and earned his doctorate in 1995 at Chiba University, Faculty of Pharmaceutical Sciences.
Fellows of DIA
-
Tatsuo Kurokawa,
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
Martin Harvey Allchurch • Principal International Affairs Officer, European Medicines Agency, European Union
-
Minnie Baylor-Henry,
JD • President, B-Henry & Associates -
Gaby Danan,
MD, PhD • Pharmacovigilance Expert -
Richard Day,
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
Marie Dray,
MBA • President, International Regulatory Affairs Group LLC -
Nancy A. Dreyer,
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
Ron Fitzmartin,
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
E. Stewart Geary,
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
Ken Getz,
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
Alberto Grignolo,
PhD • Corporate Vice President
PAREXEL International -
Yves Juillet,
MD • Senior Vice-President, Industrie Sante -
Sandra L. Kweder,
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
Murray M. Lumpkin,
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
Sandra A. Milligan,
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
Noriaki Murao,
MS • Representative, NM Consulting -
Jennifer Riggins,
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
Jeffrey Sherman,
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
Per Spindler,
DVM, MBA • Director Biopeople, University of Copenhagen -
Ling Su,
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures